stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Revenue growth
NeoGenomics, Inc.'s revenue growth over the twelve months to 30 September 2026 was 11.1%, up 1.0 percentage points from fiscal 2025 (10.1%). Over the past ten years it has ranged from 3.64% (fiscal 2017) to 132.3% (fiscal 2016); the current reading is higher than 45% of that period. That is above the Diagnostics & Research industry median of 8.99% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 10.1% | (1.54) |
| FY2024 | 11.7% | (4.42) |
| FY2023 | 16.1% | 10.83 |
| FY2022 | 5.24% | (3.73) |
| FY2021 | 8.97% | 0.26 |
| FY2020 | 8.71% | (39.02) |
| FY2019 | 47.7% | 32.54 |
| FY2018 | 15.2% | 11.55 |
| FY2017 | 3.64% | (128.63) |
| FY2016 | 132.3% | 117.65 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 11.4% | 0.22 |
| Jun 2026 | 11.2% | 0.12 |
| Mar 2026 | 11.1% | 0.53 |
| Dec 2025 | 10.6% | (1.34) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| CDNA CareDx, Inc. compare | 38.9% |
| WGS GeneDx Holdings Corp. compare | 25.4% |
| ADPT Adaptive Biotechnologies Corporation compare | 17.9% |
| VCYT Veracyte, Inc. compare | 17.5% |
| PSNL Personalis, Inc. compare | 16.9% |
| NEO NeoGenomics, Inc. | 11.1% |
| CSTL Castle Biosciences, Inc. compare | 9.78% |
| OPK OPKO Health, Inc. compare | −21.9% |
| FRNM Freenome, Inc compare | — |
| Diagnostics & Research industry median | 8.99% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement